Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies. Schmid-Grendelmeier P, Gooderham MJ, Hartmann K, Konstantinou GN, et al. Allergy 2023 Nov 21. doi: 10.1111/all.15952.

Read + Share

Amedeo Smart

Independent Medical Education

Schmid-Grendelmeier P, Gooderham MJ, Hartmann K, Konstantinou GN, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies. Allergy 2023 Nov 21. doi: 10.1111/all.15952.
PMID: 37988255